LTGO’s Onzotrigine shows rapid, superior acute pain relief in late-stage trials
TradingView News reports Onzotrigine (LTGO) is in late-stage trials for acute pain, citing superior efficacy, rapid onset and opioid-sparing potential. It also notes LTG-321 is progressing in chronic pain.
Innovative Na 1.8 inhibitors are advancing through late-stage trials, with Onzotrigine showing superior efficacy and rapid onset in acute pain, and LTG-321 progressing in chronic pain.
Strong market demand, robust funding, and a differentiated clinical profile position the pipeline for significant…